Non-prostate uptake on 18F-PSMA-1007 PET/CT: a case of myeloma
Open Access
- 1 March 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in BJR|case reports
- Vol. 7 (2) , 20200102
Abstract
Prostate-specific membrane antigen (PSMA), a glycoprotein that is highly expressed in prostate cancer, has been used as a target for molecular radiotherapy as well as imaging. Over the last couple of years, 18F-PSMA gained popularity due to its longer half-life (110 min) compared to gallium 68Ga-PSMA (68 min). This has helped the dissemination beyond large metropolitan centres. In addition, due to the low background activity in the urinary bladder (1.2% injected dose over 2 h compared to 10% injected dose over 2 h for 68Ga), 18F-PSMA helps detect local recurrence or spread to pelvic nodes more readily as lesions are not masked by physiological urinary excretion. Despite excellent sensitivities of PSMA positron emission tomography modalities, it is noteworthy that PSMA expression is not specific to the prostate. A variety of normal tissues express PSMA with intense uptake noted in salivary glands, lacrimal glands, the liver, spleen, pancreas, small intestine, bladder and renal cortex. In this case report, we describe an example of non-prostatic PSMA uptake in a patient imaged with 18F-PSMA-1007 positron emission tomography/CT that showed an avid lytic lesion in manubrium. The patient was subsequently proven by biopsy to have myeloma. Our case report illustrates a potential pitfall when imaging patients with 18F PSMA-1007 and adds to the growing body of literature of non-prostatic uptake of PSMA and highlights the need for reporters to be aware of this uptake.Keywords
This publication has 16 references indexed in Scilit:
- Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer—Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostate-specific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysisEuropean Urology, 2020
- Nonprostatic diseases on PSMA PET imaging: a spectrum of benign and malignant findingsCancer Imaging, 2020
- 18F-PSMA 1007 Brain PET/CT Imaging in Glioma RecurrenceClinical Nuclear Medicine, 2019
- Detection Rate of 18F-Labeled PSMA PET/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-AnalysisCancers, 2019
- More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT2019
- Prospective comparison of 68Ga-PSMA PET/CT, 18F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2018
- 18F-PSMA-1007 PET/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kineticsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2018
- Advantage of 18F-PSMA-1007 over 68Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretionEuropean Journal of Nuclear Medicine and Molecular Imaging, 2018
- Biochemical Recurrence of Prostate Cancer: Initial Results with [18F]PSMA-1007 PET/CTJournal of Nuclear Medicine, 2018
- 18F-PSMA-1007 PET/CT Detects Micrometastases in a Patient With Biochemically Recurrent Prostate CancerClinical Genitourinary Cancer, 2017